Current concepts relating to the pathogenesis of emphysema associated with cigarette smoking is that an imbalance exists within the lower respiratory tract between neutrophil elastase and the local anti-neutrophil elastase screen, enabling uninhibited neutrophil elastase to destroy the alveolar structures over time. The possible role of alveolar macrophages in contributing to this imbalance was investigated by evaluating the ability of cigarette smokers' alveolar macrophages to inactivate alpha 1-antitrypsin (alAT), the major anti-neutrophil elastase of the human lower respiratory tract. In vitro, alveolar macrophages of smokers spontaneously released 2.5-fold more superoxide anion and eightfold more H202 than macrophages of nonsmokers (P < 0.01, both comparisons). Using a model system that reproduced the relative amounts of alveolar macrophages and aIAT found in the epithelial lining fluid of the lower respiratory tract, we observed that smokers' macrophages caused a 60±5% reduction in the ability of alAT to inhibit neutrophil elastase. In marked contrast, under the same conditions, nonsmokers' macrophages had no effect upon the anti-neutrophil elastase function of alAT. Addition of superoxide dismutase, catalase, mannitol, and methionine prevented inactivation of alAT by smokers' macrophages, implying that the release of oxidants mediated the inactivation of alAT. In addition, by utilizing a recombinant DNA produced modified form of alAT containing an active site substitution (met" -* val), the inactivation of alAT by smokers' alveolar macrophages was prevented, suggesting that the smokers' macrophages inactivate alAT by oxidizing the active site of the alAT molecule. These results suggest that in cigarette smokers, the alveolar macrophage can modulate the activity of alAT as an inhibitor of neutrophil elastase and thus play a role in the pathogenesis of emphysema associated with cigarette smoking.
Introduction
Alpha l-antitrypsin (alAT),' is a 52-kD glycoprotein that serves as the major inhibitor of neutrophil elastase, a potent
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Volume 80, November 1987, 1289-1295 serine protease that is capable of attacking most protein components of the extracellular matrix (1) (2) (3) . The critical importance of al AT as an inhibitor of neutrophil elastase is highlighted by alAT deficiency, a hereditary disorder associated with plasma alAT levels < 35% of normal and the development of emphysema in the third to fourth decades (4) (5) (6) (7) . In this context, the pathogenesis of the emphysema associated with alAT deficiency is conceptualized as an imbalance between a 1 AT and neutrophil elastase in the alveolar structures such that there is insufficient alAT to provide a protective screen against the burden of neutrophils, and hence neutrophil elastase, in the local milieu (4, 8, 9) .
The same concepts have been extended to conceptualize the pathogenesis of the emphysema associated with cigarette smoking (10) (11) (12) (13) (14) (15) . Despite the fact that most of these individuals have normal levels of a 1 AT in blood and lung (16, 17) , the knowledge that alAT can be rendered impotent by oxidation has led to the concept that cigarette smoking may lead to an inactivation of a 1 AT in the lung, leaving the lower respiratory tract without its normal anti-neutrophil elastase defenses (1, (12) (13) (14) (15) 18) . This concept is supported by in vitro studies showing that cigarette smoke will inactivate alAT by oxidative mechanisms (12, [19] [20] [21] and that the alAT recovered from the epithelial surface of the lower respiratory tract of cigarette smokers has a reduced association rate constant for neutrophil elastase (22) . Furthermore, the alAT recovered from the lung of cigarette smokers has been observed to have a decreased ability to inhibit porcine pancreatic elastase compared with the lung alAT of nonsmokers (13, 23, 24) , although this observation has been disputed (25, 26) .
Although it is compelling to invoke cigarette smoke, with its high concentration of oxidants (20) , as a source of the oxidant burden that potentially could inactivate a lAT in the lower respiratory tract, another potential source of oxidants in the lower respiratory tract of cigarette smokers are alveolar macrophages. In this regard: (a) when activated, alveolar macrophages are capable of releasing oxidants, including superoxide anion, hydrogen peroxide, and hydroxyl radical (27, 28) ; (b) the number of alveolar macrophages in the lower respiratory tract of cigarette smokers is increased severalfold (17, 29, 30) ; (c) when activated in vitro, alveolar macrophages can release sufficient oxidants to render a 1 AT an ineffective inhibitor of neutrophil elastase (31, 32); and (d) alveolar macrophages recovered from the lungs ofcigarette smokers are spontaneously releasing oxidants (29, 33 To evaluate this hypothesis, we recovered alveolar macrophages from the lower respiratory tract of nonsmokers and smokers, and evaluated the ability of these cells to modulate the activity of alAT as an inhibitor of neutrophil elastase. In addition, by utilizing a recombinant DNA-produced modified form of a1 AT containing an active site substitution (met358 val) rendering it resistant to oxidation but still active as an inhibitor of neutrophil elastase, we have demonstrated that the spontaneous inactivation ofa IAT by macrophages of cigarette smokers occurs, at least in part, by oxidation of the active site of the a IAT.
Methods
Study population. The study population consisted of 5 healthy nonsmoking individuals (three male, two female; age 31±7 yr) and 10 healthy smoking individuals (six male, four female; age 32±6 yr) with an average cigarette smoking history of 27±11 pack years. (Data is presented as mean±SE of the mean; all statistical comparisons were carried out using the two-tailed Student's t test.) All individuals were free of lung disease as determined by the combined criteria of having normal histories, physical examinations, chest x rays, and lung function tests (34) .
Lower respiratory tract inflammatory cells. Inflammatory cells were recovered from the lower respiratory tract of nonsmokers and smokers by bronchoalveolar lavage as previously described (35) . Alveolar macrophages were purified by adherence (1 h, 370) at 5 X 105 cells in 1 ml in 24-well tissue culture plates (Falcon Labware, Oxnard, CA) in RPMI medium (Gibco, Grand Island, NY) containing 10% calf serum (Whitaker M. A. Bioproducts, Walkersville, MD). In all cases the alveolar macrophages were > 95% pure and > 90% viable (as assessed by trypan blue). The volume of epithelial lining fluid (ELF) recovered, quantified using the urea method (36), was 2.0±1.0 ml for nonsmokers and 2.7±1.1 ml for smokers (P > 0.2). Concentrations of alAT in ELF were quantified using an enzyme-linked" immunoassay (in quadruplicate) with a standard aIAT that had been quantified by amino acid analysis (37) .
The spontaneous release of superoxide anion (O-) and H202 by the purified alveolar macrophages of the nonsmokers and smokers was quantified in vitro (38, 39) . Briefly, for O-, the alveolar macrophages (5 X 105/well) in 24-well plates were incubated in 0.5 ml of Hanks' balanced salt solution (HBSS; Gibco) containing 80 nm ferricytochrome c (Type III, Sigma Chemical Co., St. Louis, MO). After incubation for 30 min at 370, the amount of O" released into the medium was quantified at 550 nm. For the measurement of the spontaneous release of H202, HBSS containing 0.28 mM phenol red, 8.5 U/ml horseradish peroxidase (Type II, Sigma Chemical Co.) was added and the macrophages incubated for 30 min at 37°. The amount of H202 in the supernatant was then determined by the addition of 10 Ml of 1 N NaOH and the absorbance read at 61'0 nm. The concentration of H202 was based on a standard curve using various concentrations of reagent grade H202.
Source of aJAT. Normal human alAT was purified from the plasma of an individual homozygous for the M l(va1213) form ofalAT as identified by'the combined criteria of isoelectric focusing, serum a 1 AT levels, family studies, and BstEII restriction endonuclease mapping of genomic DNA (40, 41) . Purification ofalAT from plasma was accomplished by positive selection affinity chromatography (42) . The purified al AT was' concentrated by pressure filtration (YM-10 membrane, Amicon Corp., Danvers, MA) and stored in aliquots in liquid nitrogen vapor until use. The final preparation was > 95% pure as assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Recombinant aI AT was produced in Escherichia coli as previously Evaluation ofability ofthe alA Tpreparations to inhibit neutrophil elastase. The ability of a 1AT to inhibit neutrophil elastase was evaluated using two assays: (a) the time-dependent inhibition of equimolar concentration of neutrophil elastase and a 1 AT; and (b) the time-independent inhibition of neutrophil elastase by increasing concentrations of alAT. Both assays were carried out using a neutrophil elastase standard for which the activity had been determined (37) .
The time-dependent inhibition of purified alAT with neutrophil elastase was carried out by the method of Beatty et al. ( 11) with minor modifications described by Straus et al. (37) . In brief, the alAT was titrated using neutrophil elastase to determine the percentage of active alAT in the preparation. Equimolar amounts of elastase and active a 1 AT (I nM each) were then reacted at 230 in a 1 -ml reaction volume containing 100 mM Hepes, pH 7.5, 0.5 M NaCl, and 0.1% Brij-35.
Residual elastase activity at various times was determined by terminating the reaction by the addition of the specific neutrophil elastase substrate methoxy-succinyl-alanyl-alanyl-prolyl-valine nitroanilide (MeO-SAAPV-NA; 1 mM; Sigma Chemical Co.) and the residual elastase activity measured at 410 nm as a change in optical density per minute using a DU-7 spectrophotometer (Beckman Instruments, Fullerton, CA). At each time point the percent inhibition of elastase was then quantified.
Time-independent inhibition of neutrophil elastase by alAT was determined by incubating a fixed amount (2 nM) of active neutrophil elastase with various concentrations (0-8 nM) ofalAT at 230 for 2 h, a time at which the time-dependent assays demonstrated were at least twofold longer than necessary for reaction of neutrophil elastase with the a I AT (1 1, 49) . After the incubation, the neutrophil elastase-specific substrate MeO-SAAPV-NA was added and percent residual elastase activity was determined as previously described.
Evaluation ofability ofsmoker alveolar macrophages to spontaneously inactivate alAT as an inhibitor of elastase. The ability of smokers' alveolar macrophages to spontaneously inactivate a I AT was evaluated using an in vitro assay that mimicked the numbers of macrophages and concentrations of alAT in the epithelial lining fluid of the lower respiratory tract. To accomplish this, alveolar macrophages recovered from the lower respiratory tract of smokers and nonsmokers were exposed in vitro to purified plasma alAT (type Ml[val213] , see previous section) in a chamber designed to permit only low-molecular weight products of the macrophages to reach the a 1 AT. The chamber was divided in two sections, a lower alAT-containing section and an upper macrophage chamber. The total volume of the chamber was 1,400 Id (upper section, 1,000 ,ul + lower section, 400 Ml). Separating the chambers was a dialysis membrane (Union Carbide Corp., Danbury, CT) with a molecular weight cutoff of 12,000-14,000 kD. Alveolar macrophages (2 X 106) from a nonsmoker or a smoker were placed in HBSS containing 0.1% glucose in the upper chamber and alAT (IIMM in HBSS containing 0.1% glucose) was placed in the lower chamber. The numbers of alveolar macrophages and the amounts of a 1AT used were always in the ratio of 4.65 X 109 macrophages/Mmol alAT. This value was based on the average ratio of macrophages to a1AT recovered in the ELF of nonsmokers, and is approximately threefold less than that observed in smokers, i.e., the design was based on that found in normals and was biased against the increased ratio of macrophages to alAT present in the lower respiratory tract of smokers. Control samples contained alAT in the lower chamber but no added alveolar macrophages. After the chambers were incubated for 18 h at 370, alAT was retrieved from the lower portion of the chamber and then evaluated for its ability to inhibit neutrophil elastase, as previously described.
To demonstrate that low-molecular weight mediators of smoker alveolar macrophages that inactivated the a I AT were oxidants, parallel incubations were carried out using alveolar macrophages from smokers and purified plasma alAT but with the addition of antioxidants to the chambers. Superoxide dismutase (SOD; 400 U/ml, Type III, Sigma Chemical Co.), catalase (1,000 U/ml, bovine liver, Sigma Chemical Co.), or a combination of both antioxidants were added to both the macrophage and alAT portions of the chambers and the chambers incubated as previously described. In selected experiments the hydroxyl radical (OW) scavenger mannitol (I mM) or methionine (1 mM) (which inactivates HOCI) was added. After incubation, the a I AT was retrieved and its ability to inhibit porcine pancreatic elastase (Calbiochem-Behring Corp., La Jolla, CA) was measured. Pancreatic elastase was specifically used in this experiment because when the active site met358 residue of alAT is oxidized, the alAT molecule completely loses its ability to inhibit porcine pancreatic elastase. (In contrast, it is still able to inhibit neutrophil elastase, albeit with a markedly reduced association rate constant [ 1 1]). Thus, although porcine pancreatic elastase is not the normal physiologic target of human a 1 AT in vivo, it offers a convenient method to analyze the protective effect of antioxidants. The reaction between the aI AT recovered from the chambers and the porcine pancreatic elastase was carried out in a 1-ml reaction volume containing 100 mM Tris-HCI, pH 8.3, 0.5 M NaCl, 0.1% Brij-35, and 8 nM porcine pancreatic elastase (I 1). Varying concentrations of a 1 AT were added and the reaction mixture incubated for 3 h at 230. After incubation, the porcine pancreatic elastasespecific substrate (n-succinyl-alanyl-alanyl-alanyl-NA, I mM, Calbiochem-Behring Corp.) was added to the incubation. The residual pancreatic elastase activity was then quantified by measuring the change in optical density at 410 nm, and percent inhibition of elastase was calculated as previously described.
To directly demonstrate the involvement of the a 1 AT met358 residue as the target for the smoker alveolar macrophage-released oxidants as the mechanism for inactivating the aI AT, we carried out identical experiments as described for the smoker macrophages and the plasma a 1 AT, but recombinant forms ofa 1 AT, met358 ra 1 AT, and val358 ra 1 AT were substituted for the plasma a1 AT. Briefly, smokers' alveolar macrophages were added to the upper portion of a chamber across a dialysis membrane from either met358 a I AT or val358 a IAT in the same ratios used previously. After incubation for 18 h at 370 the recombinant a 1 AT was retrieved and evaluated for its ability to inhibit neutrophil elastase as previously described.
Results
Relationship between alveolar macrophages and alAT on the alveolar epithelial surface. 07 and H202, respectively). When considered in terms ofamounts ofalAT present in ELF, it was apparent that smokers' alveolar macrophages present a burden of oxidants markedly greater than do nonsmoker macrophages. For example, nonsmoker macrophages spontaneously released 84±12 mol/h' 07 per mol aIAT in ELF, whereas smoker macrophages released 570±120 mol/h-°2 per mol alAT (P < 0.005). The burden of H202 released by the alveolar macrophages was even greater. Smoker alveolar macrophages released 28-fold more H202 per mol of alAT in ELF than did nonsmoker alveolar macrophages ( Fig. 1 B , P < 0.001). Thus, on the average, the oxidant burden from alveolar macrophages faced by a molecule of a 1 AT within the smokers' alveolus is far greater than that within the nonsmokers' alveolus, and consequently the likelihood ofoxidative alteration ofthe properties of the a1AT molecule is correspondingly much greater within the smokers' lung than in the lung of the nonsmoker.
Analysis ofability ofnonsmoker and smoker alveolar macrophages to inactivate alA T as an inhibitor ofneutrophil elastase. When alveolar macrophages were incubated with a 1 AT in the in vitro system designed to reproduce the microenvironment of ELF, very different effects were observed between smokers' and nonsmokers' alveolar macrophages on the antielastase function of the a 1 AT present. The nonsmokers' macrophages caused almost no loss of function ofthe alAT as an inhibitor of neutrophil elastase (Fig. 2) . In contrast, smoker alveolar macrophages caused a significant loss of the antielastase function of alAT. The loss of antielastase function was present at all elastase-a 1 AT incubation intervals measured. Lack in increase in antielastase function with time suggests that a significant proportion of the population of alAT molecules were rendered completely impotent as inhibitors of neutrophil elastase. Strikingly, the ability of smokers' macro- phages to inactivate a I AT occurred despite that fact that conditions within the assay mimicked those within the nonsmokers' alveolus rather than those of the smoker alveolus. In this regard, when the number of smokers' alveolar macrophages was increased beyond the ratio of alveolar macrophages to a1AT ELF found in nonsmokers, the loss of antineutrophil activity was even greater, with the loss of activity proportional to numbers of macrophages in the chamber (data not shown). When put in the context ofthe microenvironment of the ELF of the smoker, where the ratio of macrophages per micromole alAT ELF is threefold greater than that used in this study, the observed effect upon alAT (Fig. 2) probably represents the minimum reduction of a 1 AT antielastase activity ongoing in the lower respiratory tract of smokers. Effect of antioxidants on ability of mediators released by smoker alveolar macrophages to interfere with alA T antielastase function. When antioxidants were added to the incubations containing smoker alveolar macrophages and a 1 AT, the suppression of a1AT antielastase function caused by the smoker macrophages was not observed. In this regard, addition of SOD or catalase to the chambers before the addition of smoker macrophages resulted in a suppression of the effect smoker macrophages have on the ability of the a IAT to subsequently inhibit elastase (P < 0.01 for each vs. control; Table  I ). Importantly, when both SOD and catalase were added, the subsequent ability of the a lAT to inhibit elastase was fully preserved (P < 0.005, compared with control). In contrast, when SOD and catalase were heat-inactivated, their protective effect (either alone or in combination) was not observed. Addition of mannitol or methionine (scavengers of OH' and HOCl, respectively) also resulted in partial protection of a I AT antielastase capacity (mannitol, 64 + 4, P < 0.05 vs. control; methionine, 63 + 7, P < 0.05 vs. control). These findings indicate that low-molecular weight oxidants were the mediators responsible for the observed loss of the elastase inhibitory function of a 1 AT after its incubation with smokers' alveolar macrophages. This is consistent with the observation that The met358 active site ofalA T as a targetfor smoker macrophages. The ability to produce recombinant forms of aIAT that are identical except for a single amino acid substitution at the active inhibitory site provides a means to confirm that at least part of the mechanism by which alveolar macrophages inactive a lAT as an inhibitor of elastase is by oxidizing the met358 residue at the site that is central to the elastase-inhibitory function of the alAT molecule. In this regard, cigarette smokers' alveolar macrophages caused a nearly total loss ofthe ability of met358 ra I AT to inhibit neutrophil elastase (Fig. 3 A) . In contrast, the ability of val358 ralAT, to inhibit neutrophil elastase was not significantly affected by exposure to cigarette smokers' macrophages (Fig. 3 B) . On the average, when compared with control met358 ra 1 AT not exposed to macrophages, the met358 ra 1 AT exposed to smoker macrophages was only 14±6% as active (Fig. 3 C) . In contrast, val358 ralAT retained 84±8% of its activity (P < 0.005). Because the only difference between met358 ra 1 AT and val1358 ra 1 AT is the substitution of valine for methionine at the active site of the a IAT molecule, this differential effect strongly suggests that the mechanism of suppression of a 1 AT antielastase activity by smokers' macrophages is associated with the action ofoxidants upon the active site methionine residue.
Discussion
The finding that cigarette smokers' alveolar macrophages spontaneously are releasing sufficient amounts of oxidants to modulate the neutrophil elastase-inhibitory function ofalAT provides insight into the mechanisms through which cigarette smoking is linked to a markedly increased risk for the development of emphysema. In cigarette smokers, alveolar macrophages are present in the lower respiratory tract in numbers severalfold greater than in nonsmokers (17, 29, 30 arette smokers (50) . Alveolar macrophages, by virtue of their increased numbers and exaggerated production of oxidants (29, 32, 33) , are ideal candidates to effect the functional integrity of the antielastase screen of the lower respiratory tract. In this regard, in the context ofthe present study, it is reasonable to conceptualize that macrophages create local areas within the alveolus in which there is deficient antineutrophil elastase protection due to oxidation of alAT. In this scenario, lack of antielastase screen makes these areas of the lung vulnerable to elastase released by neutrophils or by macrophages that have ingested neutrophil elastase (51, 52) . The result would be development of localized tissue destruction that ultimately may become the clinical disorder emphysema. Oxidation of alAT by smokers' alveolar macrophages is also consistent with the study by Carp et al. (23) that observed oxidized alAT in bronchoalveolar lavage fluid obtained from smokers' lungs. These observations are consistent with the knowledge that oxidized alAT has a reduced association rate constant for neutrophil elastase (1 1) and that smoker lower respiratory tract a I AT has a lower association rate constant for neutrophil elastase than does nonsmoker lower respiratory tract alAT (22). However, the demonstration that alAT can be oxidized by smokers' macrophages does not necessarily imply that a significant proportion of the alAT in all regions within the lower respiratory tract is oxidized. A more reasonable conceptualization based upon this model is that some alAT is inactivated by oxidants released by the macrophages in areas ofmacrophage accumulation. This process may not be occurring to the same degree everywhere within the lung, due to local differences in macrophage concentration, availability of antioxidants, transudation of plasma, or other factors that could have the effect of decreasing the local intensity of alveolar macrophage exposure to a 1 AT. Furthermore, because cigarette smoke itselfcan oxidize alAT, the extent, type, and technique of smoking may also influence the status of alAT in different areas of the lower respiratory tract (19, 24) . Hence, a 1 AT recovered by bronchoalveolar lavage may contain active and inactive a IAT in varying proportions. This heterogeneity may explain, at least in part, why some studies have shown that the population of alAT molecules recovered from the lower respiratory tract of cigarette smokers is relatively unable to inhibit pancreatic elastase compared with that recovered from nonsmokers (13, 23, 24) , whereas other studies have not shown such a difference (25, 26) .
The fact that alveolar macrophages in the lower respiratory tract of cigarette smokers are capable of modifying aIAT in the local milieu by oxidant mechanisms has implications for future approaches to investigating therapeutic strategies for preventing emphysema associated with cigarette smoking. First, because alveolar macrophages are replaced slowly (53, 54), this may explain why some individuals continue to develop lung destruction even after discontinuing cigarette smoking. Therefore, therapeutic modalities directed at suppressing the exaggerated oxidant release by the macrophages may be useful. Second, antioxidants may provide an important means of preserving the antielastase screen of the lower respiratory tract. Finally, while there are theoretical dangers in providing a "super" form ofalAT that cannot be inactivated, the val358 form of recombinant alAT may be one means to protect the lower respiratory tract against a burden of neutrophil elastase when there is a concomitant burden of oxidants such as those released by alveolar macrophages of cigarette smokers.
